Quarterly report [Sections 13 or 15(d)]

Note 3 - License Supplier Agreements (Details Textual)

v3.25.1
Note 3 - License Supplier Agreements (Details Textual) - USD ($)
 1 Months Ended 4 Months Ended
Apr. 24, 2025
Feb. 28, 2023
Oct. 29, 2018
Feb. 17, 2015
Dec. 31, 2019
Jun. 17, 2015
Contractual Obligation Development Expense         $ 81,500,000  
Contractual Obligation, Commercial Expense         $ 151,000,000  
AnnJi [Member]            
License Agreement, Purchase Consideration   $ 3,000,000        
Maximum Reimbursement Amount In Connection With Product Clinical Trial   10,800,000        
Maximum Reimbursement Amount In Connection With Certain Development Milestones   14,500,000        
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone   27,500,000        
Maximum Reimbursement Amount Upon Achievement of Sales Milestone   165,000,000        
AnnJi [Member] | Subsequent Event [Member]            
Payments for Repurchase of Common Stock $ 1          
Payments Upon Termination of Agreement 200,000          
Termination Payments Receivable 2,000,000          
Termination Payments Receivable Within Thirty Days 1,000,000          
Termination Payments Receivable Within Ninety Days 1,000,000          
Eligible Termination Payments, Development and Regulatory Milestones 5,000,000          
Eligible Termination Payments, Commercial Sales Milestones $ 17,000,000          
Eligible Termination Payments, Royalty Percentage on Net Sales 1.75%          
Eligible Termination Payments, Percentage of Subsequent Licensees 15.00%          
AnnJi [Member] | Minimum [Member]            
Sales Milestone Required for Maximum Reimbursement   75,000,000        
AnnJi [Member] | Minimum [Member] | Subsequent Event [Member]            
Eligible Termination Payments, Subsequent Licensees $ 4,000,000          
AnnJi [Member] | Maximum [Member]            
Sales Milestone Required for Maximum Reimbursement   $ 750,000,000        
AnnJi [Member] | Maximum [Member] | Subsequent Event [Member]            
Eligible Termination Payments, Subsequent Licensees $ 7,500,000          
Revogenex License [Member]            
Contractual Obligation, Maximum Future Payments           $ 3,000,000
Baergic Licenses [Member] | CCHMC [Member]            
Percentage of Equity Fee         5.00%  
Polpharma [Member]            
Payments to Acquire in Process Research and Development     $ 2,000,000      
Fortress Biotech Inc [Member] | Iv Tramadol [Member]            
Payments to Acquire in Process Research and Development       $ 3,000,000    
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member]            
Payments to Acquire in Process Research and Development           $ 1,000,000
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Upfront Payment [Member]            
Percentage of Equity Fee         20.00%  
Baergic Licenses [Member] | Upfront Payment [Member] | CCHMC [Member]            
Payments to Acquire in Process Research and Development         $ 200,000  
Baergic Licenses [Member] | Upfront Payment [Member] | AZERBAIJAN            
Payments to Acquire in Process Research and Development         $ 3,000,000